Glenmark Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹4,247 Cr −29.8% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
GP

Glenmark Pharmaceuticals Ltd

Q3 FY26

Glenmark Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹3,901Cr
+15.1% YoY
−35.5% QoQ
Net profit
₹403Cr
+15.8% YoY
−33.9% QoQ
Margin
22%
+4 pp YoY
−17 pp QoQ

Glenmark Pharmaceuticals Ltd Q3 FY26 key numbers

Revenue
FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS.

As stated in Glenmark Pharmaceuticals Ltd's Q3 FY26 earnings call transcript · published 3 Jul 2026. Reported figures, not investment advice.

Price₹2,318
Market cap₹63.7K Cr
P/E20.4

The short version

TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products.

From Glenmark Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17).
  • FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17).
  • India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17).
  • Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10).
  • Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9).

2 more points from Glenmark Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Glenmark Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Planned capex for the next fiscal year is around INR 700-800 crores annually.
  • Investments primarily go into:
  • Ongoing capex on plants and expanding current manufacturing lines and facilities.
  • Strategic in-licensing products such as the Hengrui asset.
  • No current in-house biologic manufacturing; biologics manufacturing is outsourced, but future developments unknown.
  • Capex mix: approximately 55% intangible assets (e.g., licensing, product acquisition) and 45% tangible assets (e.g., plant expansion).

2 more points from Glenmark Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Glenmark Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Glenmark Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Glenmark Pharmaceuticals Ltd Q3 FY26 results — key figures

Glenmark Pharmaceuticals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue3,9013,388+15.1%6,047-35.5%
Operating profit (EBITDA)870600+45%2,360-63.1%
Operating margin22%18%+4 pp39%-17 pp
Profit before tax534456+17.1%967-44.8%
Net profit (PAT)403348+15.8%610-33.9%
EPS (₹)14.2912.33+15.9%21.63-33.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.2K Cr, net profit ₹264 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Glenmark Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Glenmark Pharmaceuticals Ltd Q3 FY26 results?

TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products.

What is Glenmark Pharmaceuticals Ltd share price analysis?

Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹63,749 Cr. Investors should review the full earnings analysis for detailed insights.

Is Glenmark Pharmaceuticals Ltd planning capital expenditure?

Planned capex for the next fiscal year is around INR 700-800 crores annually.

Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.